KRAS and lung cancer: It was also found that the combination of Palbociclib and Trametinib, a specific K-ras-targeted drug, could induce the senescence of lung cancer cells with K-ras mutation, and then SASP factors could activate natural killer (NK) cells, thus improving the treatment effect on lung cancer (38).